Page last updated: 2024-12-06

parvaquone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Parvaquone is an anti-cancer drug that is used to treat a type of cancer called Kaposi's sarcoma. It works by inhibiting the growth and spread of cancer cells. Parvaquone was first synthesized in the 1970s and has been studied extensively for its potential use in treating a variety of cancers. It has been shown to be effective in treating Kaposi's sarcoma, as well as other types of cancer, such as non-Hodgkin lymphoma. Parvaquone is currently being studied for its potential use in treating other diseases, such as malaria. Parvaquone is an important drug because it is effective in treating Kaposi's sarcoma, a cancer that is often difficult to treat. It is also being studied for its potential use in treating other diseases. The drug is particularly interesting because it targets the mitochondria, an organelle that is essential for the survival of all cells. By interfering with mitochondrial function, parvaquone can kill cancer cells without harming healthy cells. However, parvaquone can also have side effects, such as nausea, vomiting, and fatigue. '

parvaquone: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71825
CHEMBL ID103124
CHEMBL ID2105306
SCHEMBL ID916441
SCHEMBL ID16621117
MeSH IDM0090644

Synonyms (35)

Synonym
nsc-631611
nsc631611
2-cyclohexyl-3-hydroxy-naphthalene-1,4-dione
2-cyclohexyl-3-hydroxynaphthoquinone
nsc278
nsc-278
2-cyclohexyl-3-hydroxy-1,4-naphthoquinone
4042-30-2
parvaquone
parvaquone [inn:ban]
parvaquonum [latin]
1,4-naphthalenedione, 2-cyclohexyl-3-hydroxy-
einecs 223-734-5
nsc 278
2-hydroxy-3-cyclohexyl-1,4-naphthoquinone
parvaquona [spanish]
CHEMBL103124
3-cyclohexyl-4-hydroxynaphthalene-1,2-dione
CHEMBL2105306
a2bh18685w ,
parvaquona
parvaquonum
unii-a2bh18685w
NCGC00345333-01
parvaquone [mi]
parvaquone [inn]
parvaquone [mart.]
JBFUOGRCSLVENL-UHFFFAOYSA-N
2-cyclohexyl-3-hydroxy-naphthalene-1.4-dione
SCHEMBL916441
SCHEMBL16621117
2-cyclohexyl-3-hydroxynaphthalene-1,4-dione
Q27273529
DTXSID00877991
3-cyclohexyl-4-hydroxy-1,2-dihydronaphthalene-1,2-dione

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" parva, menoctone cured all of 7 cattle at a total dosage of 10 mg/kg injected intravenously (i."( Experimental therapy of theileriosis.
McHardy, N, 1979
)
0.26
" Imidocarb, at a dosage of 4 mg/kg of body weight, given IM at 72-hour intervals 4 times, was ineffective in eliminating B equi-carrier infection in 9 mature geldings."( Imidocarb and parvaquone in the treatment of piroplasmosis (Babesia equi) in equids.
Gipson, CA; Kuttler, KL; Zaugg, JL, 1987
)
0.63
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID213066In vitro concentration required to reduce the proportion of schizont infected cells in the culture to 50% of that of untreated control in the 48 hr incubation period1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
In vitro activity of 2-alkyl-3-hydroxy-1,4-naphthoquinones against Theileria parva.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (36)

TimeframeStudies, This Drug (%)All Drugs %
pre-199026 (72.22)18.7374
1990's7 (19.44)18.2507
2000's3 (8.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.21 (24.57)
Research Supply Index3.64 (2.92)
Research Growth Index4.06 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (2.78%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other35 (97.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]